Therefore, in the present study, we conducted an update system review and meta-analysis to combine all available publications on pharmacogenetic studies, and derived more precise and comprehensive assessment on the reliable associations of the commonest XRCC1 genetic polymorphisms on the efficacy and clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. This evidence concerns the gene XRCC1 and lung carcinoma.